 Context Therapeutics NASDAQ:CNTX Inc has told investors that an abstract on the results of the monotherapy portion of its ongoing Phase 2 trial of lead candidate onapristone extended release ONA-XR in granulosa cell tumors of the ovary was accepted for oral presentation at the 2022 American Society of Clinical Oncology ASCO annual meeting. The meeting takes place from June 3-7, 2022 at the McCormick Place Convention Center in Chicago, Illinois. 